About - JNJ :

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Employees - 138100, CEO - Mr. Joaquin Duato, Sector - Healthcare, Country - US, Market Cap - 385.14B

Altman ZScore(max is 10): 2.91, Piotroski Score(max is 10): 7, Working Capital: $5572000000, Total Assets: $180104000000, Retained Earnings: $0, EBIT: 17442000000, Total Liabilities: $108614000000, Revenue: $88821000000

AryaFin Target Price - $208.3 - Current Price $159.82 - Analyst Target Price $169.61

Stats & Key Metrics
TickerJNJ
IndexDJIA, S&P 500
Curent Price 159.82
Change2.87%
Market Cap385.14B
Average Volume9.46M
Income14.07B
Sales88.82B
Book Value/Share29.70
Cash/Share10.18
Dividend Est5.02 (3.14%)
Dividend TTM4.96 (3.10%)
Dividend Ex-DateFeb 18, 2025
Employees138100
Moving Avg 20days-1.73%
Moving Avg 50days0.24%
Moving Avg 200days2.14%
Shares Outstanding2.41B
Earnings DateApr 15 BMO
Inst. Ownership72.99%
Key Ratios & Margins
Price/Earnings27.57
Forwad P/E14.48
PE Growth5.43
Price/Sales4.34
Price/Book5.38
Price/Cash15.71
Price/FCF19.41
Quick Ratio0.86
Current Ratio1.11
Debt/Equity0.53
Return on Assets8.09%
Return on Equity20.06%
Return on Investment13.61%
Gross Margin68.71%
Ops Margin23.52%
Profit Margin15.84%
RSI47.70
BETA(β)0.40
From 52week Low13.61%
From 52week High-5.98%
Earnings & Valuation
EPS5.80
EPS next Year11.04
EPS next Qtr2.64
EPS this Year5.66%
EPS next 5 Year5.08%
EPS past 5 Year0.55%
Sales past 5 Year2.03%
EPS Y/Y3.69%
Sales Y/Y-4.51%
EPS Q/Q-15.14%
Sales Q/Q5.27%
Sales Surprise0.40%
EPS Surprise2.43%
ATR(14)3.30
Perf Week-2.03%
Perf Month-3.21%
Perf Quarter10.51%
Perf Year1.33%
Perf YTD10.51%
Target Price169.61

AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer